Puma Biotechnology, Inc. — Q1 2014 Form 10-Q
Business context and reporting period
Reports the three months ended March 31, 2014. Puma is a development-stage biopharmaceutical company focused on acquiring and developing cancer drug candidates. It had no product sales or other product revenue. Its lead program is oral neratinib (PB272); the company also describes intravenous neratinib and PB357. The filing identifies ongoing development across multiple cancer indications.
Financial position and results
| Metric | Q1 2014 / March 31, 2014 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $16.294 million | $9.532 million in Q1 2013 |
| General and administrative expense | $3.525 million | $2.274 million in Q1 2013 |
| Total operating expenses / loss from operations | $19.819 million | $11.806 million in Q1 2013 |
| Net loss | $19.794 million; $0.67 per share | $11.780 million; $0.41 per share in Q1 2013 |
| Cash used in operating activities | $17.047 million | $18.481 million in Q1 2013 |
| Cash and cash equivalents | $163.380 million | $43.044 million at December 31, 2013 |
| Marketable securities | $32.734 million | $40.904 million at December 31, 2013 |
| Working capital | $191.420 million | $77.125 million at December 31, 2013 |
| Total liabilities | $21.466 million | $20.387 million at December 31, 2013 |
Amounts are in U.S. dollars; statement figures are in thousands unless otherwise noted. The company reported no debt balance in the presented balance sheet; current liabilities were primarily accounts payable and accrued expenses. Profit margins are not applicable given the absence of revenue.
Material changes versus prior comparable period
- Net loss increased by $8.014 million year over year as operating expenses rose 68%, led by R&D expense growth of 71% and G&A growth of 55%.
- R&D costs increased with expanded clinical activity, employee growth, and higher stock-based compensation. R&D headcount rose from 50 to 73; G&A headcount rose from 8 to 13.
- Operating cash outflow was lower than in Q1 2013, while cash and cash equivalents rose substantially following the February 2014 public offering. The offering generated $129.440 million in net proceeds from 1,126,530 shares.
- Licensor receivable increased to $13.296 million from $9.813 million at December 31, 2013. The filing says a $4.7 million payment was received in April 2014, after quarter-end.
Outlook, commentary, and risks
- Management estimated cash, cash equivalents, and marketable securities of approximately $196.1 million, plus the $13.3 million licensor receivable, would fund anticipated operations through 2015 and into 2016. It said additional capital may be sought earlier and that funding after that period will be needed unless the company becomes profitable.
- For the next 12 months, management estimated R&D spending of $60–65 million and G&A spending of $7–8 million, both excluding stock-based compensation. It expected continued hiring and increased clinical-development costs.
- The company expected to continue incurring losses and negative operating cash flows. Future financing is not committed; unavailable or unfavorable financing could force delays or discontinuation of development programs, and equity financing could dilute shareholders.
- Clinical-trial timing, enrollment, safety and efficacy results, manufacturing costs, regulatory approvals, and whether programs are developed with partners are significant uncertainties. Management said it did not expect product approval until approximately 2015, assuming no unforeseen safety issues.
- The $13.296 million licensor receivable relates to reimbursable legacy-trial costs; no reserve was recorded. Collection timing depends on the licensor’s review of invoices and supporting documentation.
- Stock-based compensation was $5.163 million in Q1 2014, up from $1.175 million. The company also presented non-GAAP results excluding stock compensation; these are not substitutes for GAAP results.
- Management reported effective disclosure controls as of March 31, 2014, no material change in internal control over financial reporting, no material pending legal proceedings, and no material change to risk factors disclosed in its 2013 Form 10-K.
Important facts for investors to verify
- Clinical-trial progress, safety and efficacy data, and regulatory milestones for neratinib and other candidates.
- Collection and timing of the licensor receivable, including subsequent receipts and any future reserve assessment.
- Actual cash burn and spending versus management’s forward estimates, including the effect of stock-based compensation.
- Runway assumptions, future financing needs, availability and terms of capital, and potential dilution.
- Share-count changes and outstanding options, performance shares, and warrants when assessing dilution.